clinical trial · NCT06033742
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects
Jiangsu Hansoh Pharmaceutical Co., Ltd.·phase1·completed·n = 84
PsoriasisHS-10374 tabletsHS-10374-matched placebo tablets
brief summary
The purpose of this first-in-human study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of HS-10374 in healthy subjects.
started
Nov 13, 2021
primary completion
Mar 24, 2023
completion
Mar 24, 2023
last updated
Sep 13, 2023
official title
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HS-10374 in Healthy Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol